COMPUTATIONAL SCREENING AND MOLECULAR DOCKING OF LICHEN SECONDARY METABOLITES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-COV-2 MAIN PROTEASE AND SPIKE PROTEIN

SENTHIL PRABHU S; SATHISHKUMAR R; KIRUTHIKA B

doi:10.22159/ajpcr.2021.v14i12.43227

Authors

SENTHIL PRABHU S Department of Microbiology, Dr. N.G.P. Arts and Science College, Coimbatore, Tamil Nadu, India;
SATHISHKUMAR R Department of Biotechnology, Kongunadu Arts and Science College, Coimbatore, Tamil Nadu, India;
KIRUTHIKA B Executive Board Member-Secretary, NJ Academy of Science Union, New Jersey, USA.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i12.43227

Keywords:

Coronavirus disease-19, Severe acute respiratory syndrome coronavirus-2, Docking, Lichen Compounds, Main protease, Spike protein

Abstract

Objective: At present, the coronavirus disease (COVID)-19 pandemic is increasing global health concerns. This coronavirus outbreak is caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2. Since, no specific antiviral for treatment against COVID-19, so identification of new therapeutics is an urgent need. The objective of this study is to the analysis of lichen compounds against main protease and spike protein targets of SARS-CoV-2 using in silico approach.

Methods: A total of 108 lichen compounds were subjected to ADMET analysis and 14 compounds were selected based on the ADMET properties and Lipinski’s rule of five. Molecular docking was performed for screening of selected individual lichen metabolites against the main protease and spike proteins of SARS-CoV-2 by Schrodinger Glide module software.

Results: Among the lead compounds, fallacinol showed the highest binding energy value of −11.83 kcal/mol against spike protein, 4-O-Demethylbarbatic acid exhibited the highest dock score of −11.67 kcal/mol against main protease.

Conclusion: This study finding suggests that lichen substances may be potential inhibitors of SARS-CoV-2.

Downloads

Download data is not yet available.

References

Moore N. Chloroquine for COVID-19 infection. Drug Saf 2020;43:393-4.

Ul Qamar MT, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020;10:313-9.

World Health Organization, Report; 2021. Available from: https:// covid19.who.int

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Evaluation and Treatment Coronavirus (COVID-19). Treasure Island, FL, USA: Stat Pearls Publishing LLC; 2020.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-62.

Gabutti G, d’Anchera E, Sandri F, Savio M, Stefanati A. Coronavirus: Update related to the current outbreak of COVID-19. Infect Dis Ther 2020;4:1-3.

Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117-477.

Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.

Pandey P, Rane JS, Chatterjee A, Kumar A, Khan R, Prakash A, et al. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: An in silico study for drug development. J Biomol Struct Dyn 2021;39:6306-16.

Okuyama E, Umeyama K, Yamazaki M, Kinoshita Y, Yamamoto Y. Usnic acid and diffractic acid as analgesic and antipyretic components of Usnea diffracta. Planta Med 1995;61:113-5.

Vijayakumar CS, Viswanathan S, Reddy MK, Parvathavarthini S, Kundu AB, Sukumar E. Anti-inflammatory activity of (+) -usnic acid. Fitoterapia 2000;71:564-6.

Rashid MA, Bhuiyan MS, Hossain MA, Quader MA, Nutan MT, Karim MR. (+)- Usnic acid, an antimicrobial agent from Permelia kamtschandalis. Pak J Microbiol 2001;1:26-8.

Esimone CO, Grunwald T, Nworu CS, Kuate S, Proksch P, Uberla K. Broad spectrum antiviral fractions from the lichen Ramalina farinacea (L.) Arch Chemother 2009;55:119-26.

Eugenia C, Pereira SC, Nascimento RC, Lima NH, Silva AF, Oliveira EB, et al. Analysis of Usnea fasciata crude extracts with antineoplastic activity. Tokai J Exp Clin Med 1994;19:47-52.

Dong S, Sun J, Mao Z, Wang L, Lu YL, Li J. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV). J Med Virol 2020;2:1542-8.

Sreeja S, Smith AA, Madan S, Sunilkumar D, Vani V. Computational molecular modelling of 2-aminobenzimidazole derivatives: Strong successor of hypoglycaemic agent. Int J Pharm Pharm Sci 2021;13:16-21.

Badavath VN, Sinha BN, Jayaprakash V. Design, in-silico docking and predictive ADME properties of novel pyrazoline derivatives with selective human mao inhibitory activity. Int J Pharm Pharm Sci 2021;7:277-82.

Murgueitio MS, Bermudez M, Mortier J, Wolber G. In silico virtual screening approaches for anti-viral drug discovery. Drug Discov Today Techno 2012;19:219-25.